Kintor Pharmaceutical shares soared 17.51%
Kintor Pharmaceutical shares soared 17.51%
Shares of the Chinese drug developer-- $KINTOR PHARMA-B(09939.HK)$ increased 17.51% to 25.50 as at 11:04 am.
中国药品开发商的股票--$金达医药-B(09939.HK)$截至上午11：04，增长17.51%至25.50
Accomplish Kintor's First Sales Revenue RMB34.23M in 2021
2021年实现Kintor首个销售收入3423万元人民币
• Upfront payment of out-licensing contract with Fosun Pharma in India and 28 African countries
·在印度和28个非洲国家预付与复星国际医药公司签订的外部许可合同
• Upfront payment of out-licensing contract with Etana in Indonesia
·预先支付与印度尼西亚Etana签订的外部许可合同
Pioneer of Chinese Innovative Drugs' Globalization
中国创新药物全球化的先行者
• 3 phase III MRCTs were approved by various countries' administration (FDA included)
·3个第三阶段MRCT得到了各国政府(包括FDA)的批准
• 4 drug candidates（proxalutamide, pyrilutamide, ALK-1 antibody, GT20029）have clinical trials carried out within and out of China.
·4种候选药物(丙沙鲁胺、吡鲁胺、ALK-1抗体、GT20029)在中国境内外进行了临床试验。
Kintor said before the start of trading that a clinical trial for its proxalutamide drug candidate had effectively reduced the risk of hospitalization and death in outpatients with mild-to-moderate cases of Covid-19, including patients with high-risk factors such as older age.
Kintor在开盘前表示，其候选丙沙鲁胺药物的临床试验有效地降低了新冠肺炎轻中度病例(包括年龄等高危因素患者)门诊患者的住院和死亡风险。
